Gamida Cell Ltd. Ordinary Shares
GMDA
GMDA: Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
moreShow GMDA Financials
Recent trades of GMDA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by GMDA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Culturing of mesenchymal stem cells with fgf4 and nicotinamide Aug. 14, 2018
-
Patent Title: Methods of culturing and expanding mesenchymal stem cells Feb. 14, 2017
-
Patent Title: Enhancement of natural killer (nk) cell proliferation and activity Nov. 03, 2015
-
Patent Title: Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the sir2 family of enzymes Mar. 24, 2015
-
Patent Title: Methods of improving stem cell homing and engraftment Sep. 30, 2014
-
Patent Title: Methods of controlling proliferation and differentiation of stem and progenitor cells Jun. 19, 2012
-
Patent Title: Expansion of stem/progenitor cells by inhibition of enzymatic reactions catalyzed by the sir2 family of enzymes May. 29, 2012
-
Patent Title: Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells Dec. 20, 2011
-
Patent Title: Expansion of renewable stem cell populations Jun. 07, 2011
-
Patent Title: Methods of controlling proliferation and differentiation of stem and progenitor cells Dec. 21, 2010
-
Patent Title: Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby Feb. 02, 2010
Federal grants, loans, and purchases
Followers on GMDA's company Twitter account
Number of mentions of GMDA in WallStreetBets Daily Discussion
Recent insights relating to GMDA
Recent picks made for GMDA stock on CNBC
ETFs with the largest estimated holdings in GMDA
Flights by private jets registered to GMDA